EPACK Prefab Technologies (EPACKPEB) — Investment Thesis

Status: OWNED (451 shares, ₹1.03L invested, 10% of portfolio)

Quality Score: 17/25 (Grade B: Good Business)

Classification: Multi-Bagger Candidate (Quality B + Base case 2.3x/3yrs, 31% CAGR)

Last Updated: 2026-04-09 | CMP: ₹177 | Entry: ₹195.06 (751 shares) | P&L: -9.2%

Data Source: Screener.in (consolidated), Q3 FY26 concall

> Recommendation: HOLD / ADD below ₹155. India's PEB penetration is 15% vs 70%+

> globally — EPACK is the market leader deploying capital at 23% ROCE into this structural

> gap. At ₹149 (18x PE), the market prices in only 15% growth versus our 22% estimate;

> base case implies 2.3x in 3 years (31% CAGR). Key condition: Q4 FY26 revenue must

> exceed ₹400 Cr to confirm FY26 guidance of ₹1,500 Cr.

Summary Verdict

Why this business?

India builds only 15% of its industrial structures using pre-engineered buildings (PEB — factory-made steel structures assembled on-site, like Lego for industrial buildings), versus 70%+ in the US, China, and Europe. This gap is closing — PLI (Production Linked Incentive) factories, data centres, warehouses, and cold chains all need PEB structures, and the economics are compelling (30-40% cheaper than conventional construction, 50% faster to build). EPACK is the market leader in a specific high-value niche: building factories for consumer durable OEMs (Original Equipment Manufacturers — Daikin, Samsung, LG, Haier, Godrej) expanding manufacturing in India. The company earns 23% ROCE (Return on Capital Employed — for every ₹100 of capital in the business, it generates ₹23 of operating profit), retains all earnings for growth, and is expanding capacity 30% into a market where demand is pre-identified and structural. The bet is simple — India's industrial construction modernises over the next decade, EPACK rides that wave with funded expansion and sticky OEM relationships, and the current 18x PE (Price-to-Earnings ratio) at a 52-week low doesn't reflect the growth that's coming.

Strengths

• Structural tailwind with decades of runway. PEB penetration in India at 15% vs 70%+ globally. Industry growing at 12-13% CAGR. EPACK growing at 2-3x industry rate. This is secular, not cyclical.
• Strong return on capital. ROCE 23.7%, ROE 22.8% — exceptional for a construction-adjacent business. PEB asset turns of 6-7x explain how 10% OPM generates 23% ROCE. Working capital days currently 8 but management guides normalised 33-35 days — still good, but the current number is artificially low from stretched payables.
• Promoter-led, well-capitalised. Promoter at 65.06%, no pledge. IPO raised ₹504 Cr (Sep 2025), D/E (Debt-to-Equity ratio) improved from 0.89 to 0.32. Capacity expansion fully funded.
• Visible revenue pipeline. Order book ₹1,216 Cr (Jan 2026) = 7-8 months visibility. 9M FY26 revenue ₹1,054 Cr (+41% YoY). ICRA upgraded credit rating to A+.
• Niche positioning in high-value PEB segment. Consumer durable OEM clients (Daikin, Samsung, LG) are stickier and better-paying than commodity industrial clients. End-to-end capability (design + fabrication + erection + EPS insulation panels) captures higher project value (₹6-7L per metric tonne vs ₹4-5L/MT for fabrication-only players).

Concerns

• Steel cost exposure is real and partially unhedged. Steel is 50-60% of input cost. PEB contracts have limited real-time pass-through — a 20% steel price spike compresses OPM from 10% to 6-7% before escalation clauses activate. This is the single biggest external risk.
• Incremental ROIC on IPO capital is unproven. The ₹300 Cr fresh issue (Sep 2025) is being deployed into 3 new facilities simultaneously. Current incremental ROIC (FY22→FY25) measures only 10% because the IPO capital hasn't yet generated returns. Need FY27 data to see if deployed capital earns adequately.
• Customer concentration in consumer durable OEMs. Exact revenue split not disclosed, but heavy dependence on Daikin/Samsung/LG factory expansions. If PLI disbursements slow or these companies defer capex, EPACK's niche suffers more than diversified peers.
• Revenue is project-based, inherently lumpy. Q3 FY26 was ₹325 Cr vs Q2's ₹434 Cr (-25% QoQ) — monsoon delays in South India. This creates noise around thesis validation. Each quarter looks volatile even if the annual trajectory is on track.

The Compounding Equation

EPACK earns 23.7% ROCE on existing capital and reinvests 100% of earnings (zero dividend). But wait — how can a business with thin 10-11% operating margins (OPM) generate 23%+ returns on capital? This is the key insight:

How thin margins produce high ROCE — a worked example:

ROCE = Profit Margin × Capital Turnover (how many times you rotate your capital through the business per year).

Imagine two businesses, each with ₹100 Cr of capital employed:

Both earn similar ROCE, but through completely different mechanisms. EPACK's trick is capital efficiency — working capital days are just 8 (meaning money comes back in 8 days), because payable days (103) exceed debtor days (66) + inventory days (73). In plain terms: EPACK collects from customers and holds supplier payments long enough that the business essentially runs on other people's money. It doesn't need much of its own capital to generate revenue, so even a thin 10% margin on that revenue produces a high return on the small amount of capital tied up.

This is why ROE (Return on Equity — 22.8%) can be high despite seemingly thin margins. The margin isn't the point — the capital efficiency is. And capital efficiency is structural to PEB: projects are short-cycle (3-6 months), steel is bought and fabricated quickly, and customers pay advances.

The growth fuel is physical: current PEB capacity is 170,000 MTPA (Metric Tonnes Per Annum — the weight of steel structures EPACK can fabricate in a year), expanding to 220,000 MTPA by FY27. At ~70% utilisation and ₹6.7L/MT realisation (revenue per tonne of steel fabricated), the new capacity supports a revenue ceiling of ~₹2,100 Cr versus FY25's ₹1,134 Cr — that's 85% headroom before EPACK needs to build another plant. Meanwhile, the India PEB market is ₹19,000 Cr today, growing to ₹54,000 Cr by 2034. EPACK at 6% market share has decades of room before hitting any TAM (Total Addressable Market) ceiling.

Historical EPS (Earnings Per Share) has compounded at 41% CAGR (Compound Annual Growth Rate) over 5 years. I model a deceleration to 20-25% forward — still 2x the industry growth rate — because EPACK is gaining share with capacity expansion while the market itself grows at 12-13%. Management guides 33% revenue growth for FY26 alone. The margin structure is the vulnerability: a 20% steel spike without timely pass-through compresses OPM by 2-3 percentage points and temporarily stalls EPS growth. But the structural demand (PLI factories, data centres, warehousing) doesn't go away — the question is timing of margin recovery, not whether growth resumes.

What does the market think — and where do I disagree?

At ₹149 (18x PE), a reverse DCF shows the market implies ~15-16% PAT growth for the next 6 years. This barely exceeds the industry CAGR (12-13%) and implies EPACK grows roughly in line with the market — no share gains, no operating leverage from new capacity, no margin expansion. The market is pricing "competent but unremarkable."

I estimate 22% PAT CAGR, grounded in funded capacity expansion (170K → 220K MTPA) and historical execution (36% 5Y revenue CAGR, decelerating conservatively). The 6-7 percentage point gap between the market's implied growth (15%) and my estimate (22%), compounded over 5-6 years, is where the returns come from.

Why is the market wrong? Two things it's over-weighting: (1) the Q3 FY26 revenue dip — management attributes it to monsoon delays, and the Q2-strong/Q3-weak pattern is consistent with the past 3 years; (2) general small-cap de-rating since late 2025. It's under-weighting the structural PEB penetration story and the funded capacity that physically cannot produce only 15% growth if utilisation stays above 65%.

Multi-Bagger Math

Probability-weighted expected return: Bear 25% × ₹182 + Base 50% × ₹336 + Bull 25% × ₹508 = ₹341 → 2.3x in 3 years (~32% CAGR)

Odds of base case or better: ~60%. The compounding engine (23% ROCE) and runway (decades of PEB penetration catch-up) are established. At ₹149, even the bear case implies only 7% annualised downside — you lose little if wrong but gain 2-3x if right. The asymmetry is strongly favourable.

When do I sell?

1. FY26 full-year revenue comes in below ₹1,300 Cr — because management guided ₹1,500-1,550 Cr. Missing by 15%+ means either guidance was fiction or structural demand has slowed. Either destroys credibility and growth assumptions must be re-based. Source: Q4 FY26 results (May 2026).

2. OPM falls below 8% for two consecutive quarters without a steel price spike as the cause — because if margins compress from competition rather than input costs, it means EPACK's niche positioning (OEM relationships, end-to-end capability) isn't worth a premium. The business becomes a commodity fabricator at 5% net margins, which doesn't compound. Source: Screener.in quarterly P&L.

3. Order book drops below ₹800 Cr for two consecutive quarters — because this would mean OEM customers are deferring factory expansions and the project pipeline is drying up. Current order book at ₹1,216 Cr provides 7-8 months of revenue visibility; below ₹800 Cr means less than 5 months, which is insufficient for a project-based business. Source: quarterly concall disclosures.

Where does this rank?

Among current holdings, EPACK has the best risk/reward at current price. KAYNES is a better business (deeper moat, defence/aerospace exposure, OSAT optionality) but at 64x PE it's priced for perfection — EPACK offers comparable growth economics at 18x. GROWW (85x PE) needs 3+ years to grow into its valuation. SHILCTECH (53% ROE) is higher quality but already at fair value on DCF. EPACK is the only holding where the market prices in well below estimated growth AND the stock sits at a 52-week low — fundamental disagreement + price distress is a rare combination.

If deploying the next ₹1L, the top two choices are EPACK (multi-bagger upside, higher risk) and ICICIAMC (steady 15-18% compounder, lower risk). EPACK for growth, ICICIAMC for reliability.

Recent Developments

• 2026-03-22: Full framework rewrite to v2 template. Incremental ROIC measured at 10% (diluted by undeployed IPO capital) — trailing ROCE 23.7% on existing operations is the more relevant metric. ICRA upgraded credit rating to A+.
• 2026-03-19: DCF revised from conservative base ₹133 to capacity-anchored base ₹234. PEB penetration thesis (15% vs 70%+ global) added as structural anchor.
• 2026-04-09: CMP ₹177 (was ₹149 at last research). TTM Revenue now ₹1,385 Cr — strongly tracking toward FY26 guidance of ₹1,500 Cr. P/E 21.6x at current price. 52W High ₹344 / 52W Low ₹132. Portfolio: 751 shares at avg ₹195.06 (added 300 at dip). Hold — add zone ₹130-155 if Q4 disappoints, or if price returns there. Q4 FY26 (May 2026) is the key event: need revenue ≥ ₹400 Cr and full-year ≥ ₹1,500 Cr to confirm thesis. Source: Screener.in Apr 2026.

Government policy tailwinds — why EPACK's order book is structurally growing:

Three converging govt-driven waves are creating PEB demand:

1. PLI factories: 14 PLI sectors (electronics, defence, food processing, textiles, pharma) mandate new manufacturing capacity. Consumer durables PLI (₹6,238 Cr) is bringing Daikin, Samsung, LG, Haier factory expansions — EPACK's core customer base. Each PLI-mandated factory is a PEB project. India has committed ₹1.97 lakh Cr to PLI across sectors through 2026-27.

2. Data centre boom: India's digital economy expansion has triggered hyperscaler capex — Amazon, Microsoft, Google all building large data centre campuses in India. Data centres require precise climate-controlled structures with high structural loads — PEB with EPS insulated panels is the preferred build method. This is a new customer segment for EPACK beyond traditional OEM clients.

3. China+1 manufacturing diversification: Global OEMs de-risking from China are setting up India facilities. Daikin alone committed to manufacturing 100% of its India sales locally by 2027. Each new plant is a 3-6 month PEB build — EPACK captures this wave through its existing OEM relationships, reducing acquisition cost.

The structural gap between India (15% PEB penetration) and global norms (70%+) doesn't close in 3 years — it closes over 10-15 years as India's industrial base modernises. EPACK rides this gap as market leader with OEM relationships that competitors cannot replicate quickly.

• 2026-01 (Q3 FY26 results): Revenue ₹325 Cr (-25% QoQ, +22% YoY). Management attributed dip to monsoon delays in South India — deferred to Q4, not lost. FY26 guidance reaffirmed at ₹1,500-1,550 Cr.
• 2025-09 (Q2 FY26): Best quarter ever — Revenue ₹434 Cr, OPM 12%, PAT ₹29 Cr. Confirmed capacity ramp and OEM order strength.

Action

Detailed Analysis

1. Business Summary

EPACK Prefab Technologies is India's leading pre-engineered steel building (PEB) and modular structure manufacturer, providing end-to-end solutions from design to fabrication to erection. Primary customers are consumer durable MNC OEMs (Daikin, Samsung, LG, Haier, Voltas, Whirlpool, Havells, Godrej) building factories and warehouses in India — this is a unique niche versus peers who serve broader industrial/infrastructure clients. The company also manufactures EPS (expanded polystyrene) sandwich panels through group company Epack Petrochem. EPACK listed via IPO in Sep 2025 (₹504 Cr raised, mix of fresh issue ₹300 Cr + OFS ₹204 Cr), with proceeds funding capacity expansion at Ghiloth (Rajasthan), Mambattu (Andhra Pradesh), and Vithlapur (Gujarat) — taking total capacity from ~170,000 MTPA to ~220,000 MTPA by FY27.

2. Quality Score

Threshold Checks: Flags noted — (1) OCF/PAT was low in FY23 at 0.08x, improved to 1.05x+ in FY24-25; (2) Related-party transactions with Epack Petrochem (group company supplies EPS resin, 60-70% of Petrochem's sales go to EPACK) — backward integration is strategically sound but creates governance monitoring need.

3. Compounding Engine — Q&A

Q1. Is incremental ROIC genuinely high (>20%) — and is it structural, not cyclical?

ROIC calculation (FY25):

• EBIT = Operating Profit ₹116 Cr + Other Income ₹6 Cr − Interest ₹24 Cr ≈ Operating Profit proxy = ₹116 Cr
• NOPAT = EBIT × (1 − tax rate) = ₹116 Cr × (1 − 27%) = ₹84.7 Cr
• Capital Employed = Equity (₹16 + ₹337) + Borrowings ₹216 = ₹569 Cr
• ROCE = 84.7 / 569 = 14.9% (lower than Screener's 23.7% — the difference is because Screener uses net fixed assets + working capital, not total CE. Using Screener's ROCE: 23.7%)

Incremental ROIC (3-year delta, FY22→FY25):

`

NOPAT change = PAT FY25 (59) − PAT FY22 (20) = ₹39 Cr

Capital Employed FY25 = Equity 353 + Borrowings 216 = ₹569 Cr

Capital Employed FY22 = Equity 102 + Borrowings 76 = ₹178 Cr

Change in CE = ₹391 Cr

Incremental ROIC = 39 / 391 = 10.0%

`

The 10% number is misleadingly low because equity jumped from ₹102 Cr to ₹353 Cr partly due to the IPO (₹300 Cr fresh issue in Sep 2025). This capital is being deployed into new facilities that haven't yet generated revenue. The more relevant metric is trailing ROCE of 23.7% on existing operations — high for a construction-adjacent business and well above cost of capital (12-13%).

Why it's structural (not cyclical):

• PEB is a replacement technology for conventional construction — the shift is secular, not cyclical
• EPACK's OEM relationships (Daikin, Samsung, LG) create repeat project opportunities as these companies expand capacity across India
• Multi-location manufacturing (4 plants) provides geographic proximity advantage reducing logistics costs
• Working capital days of just 8 means the business model is inherently capital-efficient

Honest check: If ROCE drops below 15%, the compounding thesis breaks because PEB is fundamentally a low-margin business (OPM 10-11%) and any margin compression from steel cost spikes or competitive pricing pressure would push returns below cost of capital.

Q2. How much capital can be redeployed at these returns — what's the reinvestment runway?

Reinvestment rate (FY25):

`

Capex (investing outflow) = ₹151 Cr

Depreciation = ₹17 Cr

Net capex = ₹134 Cr

PAT = ₹59 Cr

Dividends = ₹0 (zero payout)

Reinvestment Rate = 100% (all earnings retained + external capital raised)

`

Capital deployment opportunity:

• India PEB market: ~₹19,000 Cr ($2.3B) in 2025, growing to ~₹54,000 Cr ($6.5B) by 2034 at 12.4% CAGR
• EPACK FY25 revenue ₹1,134 Cr = ~6% market share of a ₹19,000 Cr market
• PEB penetration in India: ~15% of total construction vs 70%+ in US/China/Europe
• If penetration doubles to 30% over 10 years, the TAM doubles to ₹38,000 Cr even at current prices
• EPACK at 6% share of ₹38,000 Cr = ₹2,280 Cr revenue (2x current); at 8% share = ₹3,040 Cr (2.7x)

Capacity expansion plan (funded by IPO + internal accruals):

• Current: ~170,000 MTPA PEB capacity
• Adding: Ghiloth (Rajasthan) — sandwich panels by Q3 FY27
• Adding: Mambattu (AP) — PEB expansion by Q4 FY26
• Adding: Vithlapur (Gujarat) — Phase 1 by FY27, adding 50,000 tons
• Target: ~220,000 MTPA by FY27 = 29% capacity increase

Runway estimate: 10-15 years — India PEB penetration has a long way to go (15% → 30%+ is a multi-decade shift), industrial capex is structurally growing (PLI, Make in India), and EPACK has clear capacity expansion funded and underway.

Q3. What's the implied compounding math?

Compounding formula:

`

Reinvestment Rate: ~100% (zero dividends, all retained + IPO capital)

ROIC on existing capital: 23.7% (ROCE)

Implied earnings growth = Reinvestment Rate × ROIC

Historical: 5Y Sales CAGR 36%, 5Y PAT CAGR 41%

Management FY26 guidance: ₹1,500-1,550 Cr revenue (33-34% YoY growth)

Conservative forward estimate:

g = 20-25% CAGR for next 3-5 years (decelerating from 36% historical)

At 22% CAGR for 5 years → 2.7x on intrinsic value

At 25% CAGR for 5 years → 3.1x on intrinsic value

`

• Entry multiple 18x → Exit multiple 20-22x (PEB company with growth still intact)
• At 22% PAT CAGR for 5 years: PAT grows from ₹82 Cr to ₹222 Cr
• At 20x exit P/E: market cap ₹4,440 Cr = ₹444/share = 3.0x from CMP ₹149

Smell test: 22-25% PAT CAGR for 5 years requires revenue CAGR of ~20-22% (with slight margin improvement). This is below the historical 36% CAGR and slightly above the industry 12-13% CAGR. For a company gaining market share with funded capacity expansion, this is reasonable. Passes smell test.

Q4. What breaks the thesis?

The compounding breaks if: Steel prices spike 25%+ without contract escalation clauses activating, compressing OPM from 10% to 6%, while simultaneously consumer durable OEM capex slows (PLI scheme underperforms), causing order book to drop below ₹800 Cr — the combination of margin compression + volume decline is what destroys the thesis, not either alone.

Leading indicator I'd see before the stock price tells me:

• Order book falling below ₹1,000 Cr for 2 consecutive quarters (currently ₹1,216 Cr)
• OPM dropping below 9% for 2 consecutive quarters
• Revenue run-rate falling below ₹300 Cr/quarter on a trailing basis

Q5. Can I hold through a 40% drawdown? What's my conviction anchor?

My conviction anchor (the sentence I re-read at -40%):

> India's PEB penetration is 15% versus 70%+ in developed markets — this is not a cyclical gap, it is a structural technology adoption curve. EPACK has ₹1,216 Cr of order book, funded capacity expansion to 220,000 MTPA, and OEM relationships with Daikin/Samsung/LG that will generate repeat factory construction orders for decades. The revenue is project-committed regardless of stock price.

What I will NOT do in a drawdown: I will not add more above 12% of portfolio. Current position is 10% at cost (~₹67K at market). I am already down 35%. I will hold, and only add if Q4 FY26 revenue exceeds ₹400 Cr AND OPM holds 10%+.

4. Key Metrics

P&L (Last 4 Years + TTM)

Balance Sheet (Last 4 Years + Latest)

Note: Equity jumped FY24→FY25 due to IPO fresh issue of ₹300 Cr (Sep 2025). D/E improved from 0.89 to 0.32 post-IPO. CWIP of ₹56 Cr in FY25 dropped to ₹1 Cr in Sep 2025 — capacity commissioned.

Cash Flow

Cash conversion improving. FY23 was an aberration (high working capital absorption during rapid growth). FY24-FY25 OCF/PAT >1.0x = healthy.

Key Operating Metrics

CAGRs

Quarterly Trend (Last 7 Quarters)

Pattern: Q2 (Sep) is strongest quarter, Q3 (Dec) shows monsoon-related softness. Q4 FY26 needs ₹446 Cr to hit ₹1,500 Cr guidance — achievable given Q2 FY26 was ₹434 Cr.

9M FY26: Revenue ₹1,054 Cr (+41% YoY), EBITDA ₹113 Cr (+57% YoY), PAT ₹62 Cr (+59% YoY). ICRA upgraded rating to A+ on strong H1 performance.

4b. Outlook — Base Estimate + Sensitivity

Horizon: FY28 — because capacity expansion completes by FY27, and 2 years of ramp-up needed

Primary driver: CAPACITY × UTILISATION × REALISATION

Management has reaffirmed FY26 revenue guidance of ₹1,500-1,550 Cr (33-34% YoY growth over FY25 ₹1,134 Cr). For FY27, the target is ~₹1,800 Cr (20%+ growth). Capacity is expanding from 170,000 MTPA to 220,000 MTPA by FY27 — a 29% increase. At current realisation of ~₹6.7L/MT (FY25 revenue ₹1,134 Cr on est. 170K capacity at ~70% utilisation), full utilisation of 220K MTPA capacity implies revenue ceiling of ~₹2,100 Cr.

Base Fair Value (FY28): PAT ₹125 Cr at 18x P/E = ₹2,250 Cr market cap = ₹225/share (+51% vs CMP ₹149)

Key Sensitivities

Risk/reward: Downside 15% (bear) / Upside 75% (bull) → Asymmetric upside at CMP ₹149

The one thing that makes the base case wrong: Order book fails to replenish above ₹1,000 Cr as consumer durable OEMs defer factory expansion post-PLI phase completion.

5. Valuation

• Current Price: ₹149 | Market Cap: ₹1,493 Cr | Shares: ~10.0 Cr
• 52-Week High/Low: ₹344 / ₹147
• Book Value: ₹68.7/share
• Current earnings (PAT TTM): ₹82 Cr — Source: Screener.in
• Owner Earnings (PAT + D&A − maintenance capex, est.): ₹82 + ₹21 − ₹15 (est.) = ~₹88 Cr

5.1 — Valuation Parameters

Method: Quality-adjusted DCF — Grade B (17/25)

Reverse DCF (implied growth at current price):

`

At P/E 18.1x, r = 12%, n = 6 years, Terminal Multiple = 15x:

Market Cap ₹1,493 Cr, TTM PAT ₹82 Cr

If g = 15%: Year-6 PAT = 82 × 2.31 = ₹189 Cr

Terminal = 189 × 15 = ₹2,835 Cr

PV = 2,835 / 2.01 = ₹1,410 Cr → roughly equals market cap

Implied g ≈ 15-16%

`

Market implies 15-16% PAT growth for 6 years. Our estimate: 22%. Gap = 6-7pp margin of safety.

5.2 — Margin of Safety Assessment

Reverse DCF confirms: market prices in only 15% growth — conservative relative to fundamentals.

What could go wrong (top 3 risks):

If the biggest risk materialises (steel + demand slowdown simultaneously): PAT drops to ₹45 Cr, multiple compresses to 12x → ₹54/share = 64% drawdown from CMP. This is the tail-risk scenario.

5.3 — Position Sizing

• Conviction level: Moderate
• Recommended position size: 5-8%
• Current position: 10% at cost (~6.5% at market)
• Action: HOLD. Do not add above ₹155 until Q4 FY26 confirms ₹1,500 Cr guidance. Add below ₹135 if order book holds >₹1,000 Cr.

5.4 — Valuation Models

#### Model 1: DCF (Quality-adjusted, Grade B)

Base PAT: ₹82 Cr (TTM) | FCF/PAT: 82% | Discount rate: 12% | Shares: 10.0 Cr

Bear case (g=15%, n=6, terminal 12x):

`

Year-6 PAT = 82 × (1.15)^6 = 82 × 2.31 = ₹190 Cr

Terminal Value = 190 × 12 = ₹2,280 Cr

PV of Terminal = 2,280 / (1.12)^6 = 2,280 / 1.97 = ₹1,157 Cr

PV of interim CF ≈ ₹440 Cr

Total PV ≈ ₹1,597 Cr → Per share = ₹160

`

Base case (g=22%, n=6, terminal 15x):

`

Year-6 PAT = 82 × (1.22)^6 = 82 × 3.30 = ₹271 Cr

Terminal Value = 271 × 15 = ₹4,065 Cr

PV of Terminal = 4,065 / 1.97 = ₹2,063 Cr

PV of interim CF ≈ ₹540 Cr

Total PV ≈ ₹2,603 Cr → Per share = ₹260

`

Bull case (g=28%, n=6, terminal 18x):

`

Year-6 PAT = 82 × (1.28)^6 = 82 × 4.40 = ₹361 Cr

Terminal Value = 361 × 18 = ₹6,498 Cr

PV of Terminal = 6,498 / 1.97 = ₹3,298 Cr

PV of interim CF ≈ ₹660 Cr

Total PV ≈ ₹3,958 Cr → Per share = ₹396

`

#### Model 2: P/B-ROE (Justified Price-to-Book)

Book Value: ₹68.7 | Cost of Equity: 12% | g = 6% (terminal)

Justified P/B = (ROE − g) / (CoE − g). Base: (22% − 6%) / (12% − 6%) = 16/6 = 2.67x

#### Synthesis

Verdict: Undervalued at CMP ₹149 — weighted base fair value ₹237 implies 59% upside. DCF drives the valuation because this is a growth story where reinvestment runway matters more than current book value.

"What needs to be true for 5x in 5 years?" (₹745/share)

• Market cap ₹7,450 Cr. At 22x P/E: needs ₹339 Cr PAT.
• At 8% net margin on ₹4,238 Cr revenue.
• Current revenue ₹1,385 Cr TTM. 5 years of 25% CAGR → ₹4,227 Cr. Close match.
• Probability: Low-Medium. Requires near-perfect execution + PEB market growth at 15%+ CAGR + EPACK gaining share. Possible but needs many things to go right simultaneously.

6. Competitive Landscape

Market Position

EPACK operates in India's pre-engineered building (PEB) segment, estimated at ₹19,000 Cr ($2.3B) in 2025, growing at 12-13% CAGR. The market is fragmented with 50+ players, but the top 5-6 companies (EPACK, Interarch, Zamil Steel, Kirby Building Systems, BLP Avant, Tata BlueScope) hold an estimated 35-40% share. EPACK differentiates through its focus on consumer durable OEM factory construction (Daikin, Samsung, LG) and end-to-end modular capability, whereas peers like Interarch focus more on industrial/commercial PEB and Zamil/Kirby serve infrastructure/oil & gas. EPACK's FY25 revenue of ₹1,134 Cr implies ~6% market share — still small enough that market share gains drive growth independent of industry CAGR.

Structural Advantages vs Peers

1. Consumer Durable OEM Relationships: Deep relationships with Daikin, Samsung, LG, Haier, Voltas, Whirlpool, Havells — these MNCs are building factories across India under PLI. → Competitors lack this specific OEM network → Repeat business from existing customers likely 30-40% of order book.

2. Multi-location Manufacturing (4 plants): Plants in North (Rajasthan), South (AP), and upcoming West (Gujarat) enable geographic proximity to project sites, reducing logistics cost. → Interarch has 3 plants, Zamil has 2, smaller players have 1 → Logistics/erection cost is 15-20% of PEB project value; proximity reduces this by 3-5pp.

3. End-to-End + Modular Capability: EPACK designs, fabricates, AND erects — plus manufactures EPS sandwich panels (via group company). → Most PEB companies don't do erection in-house → End-to-end captures higher project value (₹6-7L/MT vs ₹4-5L/MT for fabrication-only).

Peer Comparison

Why Multiples Differ + Re-rating Thesis

EPACKPEB at 17x PE / 2.0x P/B vs Interarch at 21x PE / 3.6x P/B:

• Interarch is near-zero debt (D/E 0.03) vs EPACK at 0.61 — lower financial risk commands premium
• Interarch has higher net margin (7.4% vs 5.2%) — better bottom-line conversion
• Interarch has been listed longer (Aug 2024 IPO vs EPACK Sep 2025) — more price discovery
• P/B gap is striking: Interarch at 3.6x book vs EPACK at 2.0x book, despite similar ROCE (~24%). This means EPACK's equity is valued at a 44% discount per rupee of book value. Either EPACK is undervalued or the market is pricing in execution risk on its ₹300 Cr IPO deployment.

Re-rating thesis: If EPACK delivers FY26 at ₹1,500+ Cr (33% growth) while Interarch grows at 25%, the growth premium should narrow. If D/E continues declining (already improved to 0.32 post-IPO), the discount to Interarch should compress from 3x P/E gap to 1-2x. At Interarch's 21x multiple on EPACK's TTM PAT ₹82 Cr → ₹172/share = 15% upside from multiple re-rating alone.

Which Has Higher Upside and Better Margin of Safety?

The P/B-ROE framework answers this directly. Justified P/B = (ROE - g) / (Ke - g), where Ke = 12% cost of equity.

EPACK trades below its justified P/B. Interarch trades 81% above its justified P/B.

Upside math (3-year forward):

Now add P/B convergence — if EPACK's P/B re-rates from 2.0x toward its justified 2.67x while Interarch mean-reverts from 3.6x toward 2.0x:

Verdict: EPACK has significantly higher upside and better margin of safety.

• EPACK is undervalued on P/B-ROE (trading at 24% discount to justified value). Interarch is overvalued (81% premium).
• EPACK's higher ROE (22% vs 18%) combined with lower valuation (17x PE, 2.0x P/B) means you're buying more compounding power per rupee invested.
• EPACK's risk is execution on IPO capital deployment — but even if ROE drops to 18% (matching Interarch), justified P/B is still 2.0x, which equals current price. Downside is protected.
• Interarch's risk is multiple compression — at 3.6x P/B on 18% ROE, there's no margin of safety. Any growth slowdown triggers a de-rating.

Cash Quality: Is the Profit Real? (EPACK vs Interarch)

A common concern with zero-dividend growth companies: are reported profits backed by real cash, or is management manipulating earnings? The test is the CFO/PAT ratio (Cash Flow from Operations divided by Profit After Tax). A ratio above 1.0x means the business generates more cash than reported profit — the opposite of manipulation. Below 0.5x consistently is a red flag.

CFO/PAT comparison — EPACK vs Interarch:

Both companies convert profit to cash adequately. EPACK's FY23 dip (0.3x) was driven by working capital build during rapid growth — receivables and inventory grew faster than payables that year. FY24 bounced back to 1.4x. Interarch's FY24 dip (0.6x) was driven by ₹223 Cr capex-related investing outflows.

Working capital comparison (where cash gets stuck):

Both are efficient. EPACK's higher payable days (105 vs ~80) means it stretches supplier payments longer — a sign of bargaining power, not weakness. Companies that fake profits typically show ballooning receivables (revenue booked but never collected); EPACK's debtor days are stable at 66.

Why zero dividend is the correct choice for EPACK (but not for a mature company):

At 23% ROCE with a 15-year runway, every rupee retained is worth 3-4x more than every rupee distributed. Interarch started paying dividends in FY25 (19% payout) because its D/E is 0.03x — it literally has more capital than it can deploy. EPACK at D/E 0.60x still has capacity expansion to fund.

Bottom line: Don't use dividends as a proxy for cash quality — use CFO/PAT instead. EPACK's 1.4x average is clean. The zero dividend is a capital allocation choice (reinvest at 23% ROCE into a growing market), not a red flag. Interarch's dividend signals a different stage of life (fully funded, nowhere to deploy), not superior governance.

Competitive Dynamics

• Market share trend: Gaining — EPACK revenue CAGR 36% vs industry 12-13%. Clear outperformance.
• Primary competitive threat: Interarch Building Solutions — listed, near-zero debt, comparable ROCE, growing at 25%+, competing for the same industrial PEB orders. Probability of margin pressure: Medium.
• Key vulnerability: Consumer durable OEM concentration — if Daikin/Samsung/LG slow India factory expansion, EPACK's specific niche suffers more than diversified peers.
• Policy tailwind: PLI scheme (12 sectors, ₹1.97L Cr outlay), National Infrastructure Pipeline, PM Gati Shakti — all require factory/warehouse construction = PEB demand. Data centre buildout (Adani, Nxtra, Yotta, Microsoft) needs large column-free spans = PEB's core strength.

7. Risks

7a. Sectoral & Technology Analysis

Tailwinds

Headwinds

Technology Considerations

• Mature, low-tech manufacturing: PEB is structural steel fabrication — no IP moat. Advantage comes from scale, execution quality, and client relationships.
• No near-term disruption risk: Modular/3D-printed construction remains niche in India. PEB position not under technological threat within 5-10 year horizon.
• EPS/insulated panel premium: Growing demand for energy-efficient buildings (cold chains, data centres, pharma) where insulated panels command higher margins. EPACK's backward integration into EPS resin positions it for this.

8. Exit Triggers

• [ ] ROE drops below 15% for 2 consecutive quarters
• [ ] OPM drops below 8% for 2 consecutive quarters (margin erosion from steel/competition)
• [ ] FY26 full-year revenue below ₹1,300 Cr (well below ₹1,500 Cr guidance = credibility damaged)
• [ ] Order book falls below ₹800 Cr (insufficient pipeline for 20%+ growth)
• [ ] Promoter holding drops below 55% without clear strategic rationale
• [ ] D/E exceeds 1.0x (post-IPO should be declining, not rising)

9. Review Schedule

• Next quarterly check: Q4 FY26 results (April/May 2026) — THE critical check. Must deliver ₹400+ Cr revenue to hit FY26 guidance.
• Key events to watch:
• Q4 FY26 results: revenue, OPM, order book update
• Mambattu (AP) facility commissioning (Q4 FY26 expected)
• Ghiloth (Rajasthan) sandwich panel facility (Q3 FY27 expected)
• Gujarat (Vithlapur) Phase 1 progress
• Steel price trends (HRC/domestic)
• Annual report FY26 — related party transactions detail

9a. External Analyst Views — YouTube Transcript Analysis (4 transcripts, same analyst)

Source: /data/transcripts/epack.md — 4 Hinglish video transcripts covering EPACK post-IPO analysis, Q2/Q3 FY26 results, and Interarch comparison. Same unnamed analyst across all 4.

Where the transcripts CONFIRM our thesis

Where the transcripts CHALLENGE our thesis

1. Repeat customer rate is weaker than we assumed.

Our thesis mentions "sticky OEM relationships" as a core moat. But the transcript reveals EPACK's repeat customer rate is only 40-45% vs Interarch's 80-85%. This is a significant gap. Interarch's clients come back nearly 9 out of 10 times; EPACK's come back less than half the time. This means:

• Customer acquisition costs are structurally higher for EPACK
• The "OEM relationship moat" may be thinner than we thought — if Samsung builds one factory with EPACK, they might use Interarch for the next one
• Revenue predictability is lower

Our response: Downgrade the moat claim. The OEM relationship is a positioning advantage, not a switching-cost moat. Interarch's model produces stickier economics.

2. EPACK is a hybrid business, not a pure PEB play.

The analyst makes a nuanced distinction: Interarch does 100% PEB (complex, high-engineering, data centres, EV plants, semiconductor factories). EPACK does PEB + prefab (modular toilets, worker shelters, PMAY housing) + packaging (thermocol for LG). The prefab segment needs less customization and has lower barriers to entry. Our thesis treats EPACK as a pure PEB company — it's not. Roughly 15% is packaging (low-growth, LG-dependent) and some portion of "PEB" revenue is actually simpler prefab work.

Our response: This is a valid critique. Interarch's pure PEB focus gives it higher entry barriers in the fastest-growing segments (data centres, renewables, semiconductors). EPACK's hybrid model dilutes the quality of revenue. We should adjust MOAT score consideration.

3. FY27 growth guidance was CUT from 30-35% to 20%.

In the Q2 con-call, management guided 30-35% medium-term growth. By Q3, this was revised to "20% on a safer side" citing geopolitical uncertainty. Even if actual delivery is higher, guidance cuts signal either:

• Management is sandbagging (benign — under-promise, over-deliver)
• Genuine demand slowdown visible to management but not yet in numbers (concerning)

Our response: Our base case uses 22% EPS CAGR. The revised 20% guidance is below our estimate — if that's the actual growth rate (not sandbagging), our base case fair value needs minor downward revision. Monitor FY27 Q1 for confirmation.

4. Export potential is limited.

The analyst explicitly says US export is NOT viable for PEB (6-7 week shipping destroys the speed advantage that IS PEB's value proposition). Only Middle East and Africa are target export markets. Currently 98-99% domestic.

Our response: Our thesis didn't model export upside, so this doesn't hurt us. But it means the TAM is genuinely India-only. International expansion via local manufacturing (like Penar Industries in the US) is capital-intensive and not on EPACK's horizon.

5. Working capital advantage is unsustainable.

We highlight "working capital days just 8" as a strength. The transcript reveals management itself says normalized WC will be 33-35 days, not 8 — current numbers are artificially good due to stretched payable days. This means:

• Our "8-day WC cycle" claim overstates the structural advantage
• As the business normalises, ₹30-40 Cr more working capital will be needed
• This will show up as lower CFO in coming quarters

Our response: Correct our thesis. 33-35 days is still very good for a construction-adjacent business, but 8 days was too good to be sustainable and we should have flagged this.

6. Packaging segment has LG concentration risk.

LG is 50-60% of the packaging segment's revenue. Packaging is 15-16% of total revenue. So LG is ~8-9% of total EPACK revenue through one segment alone. If LG shifts packaging suppliers, that's an 8% revenue hit with no warning.

Our response: Add to concerns. Not thesis-breaking but a monitoring item.

New data points to incorporate

Honest assessment: Is Interarch a better business?

The analyst thinks so ("slightly better model holistically"), and the data supports it:

Interarch is arguably the higher-quality business. But EPACK is significantly cheaper. The question is whether EPACK's discount is justified (weaker model, hybrid dilution, lower repeat rates) or excessive (market hasn't priced in renewable sector breakthrough, capacity ramp, IPO capital deployment).

Our view: The discount is excessive at 2.0x P/B vs justified 2.67x. Interarch is premium at 3.6x P/B vs justified 2.0x. At today's prices, EPACK offers better risk-adjusted returns despite being the slightly weaker business. But we should be honest: if both were at the same P/E, we'd pick Interarch.

11. Research Log

New learnings, commentary, and thesis updates — most recent first.

Full edit history: git log research/EPACKPEB.md

2026-03-28 — YouTube transcript analysis (4 videos) + Cash quality analysis

• 4 Hinglish transcripts analysed (same unnamed analyst): Full company analysis, Q2/Q3 FY26 con-call breakdowns, Interarch comparison.
• Thesis confirmations: PEB penetration tailwind, 20%+ ROCE, capacity expansion timeline, order book, margin guidance all align with our research.
• Thesis challenges identified (honest):

1. Repeat customer rate only 40-45% vs Interarch's 80-85% — OEM relationship moat is thinner than we claimed

2. EPACK is hybrid (PEB + prefab + packaging), not pure PEB — Interarch has higher barriers in fastest-growing segments

3. FY27 growth guidance cut from 30-35% to 20% — below our 22% base case

4. Working capital 8 days is unsustainable — management guides 33-35 days normalised

5. Packaging segment has LG concentration risk (50-60% of segment = ~8% of total revenue)

• New positive: Renewable energy now 25-30% of order book — sector diversification beyond consumer durables
• Honest verdict on Interarch vs EPACK: Interarch is arguably the better business (pure PEB, 85% repeat, near-zero debt, higher margins). But EPACK is significantly cheaper (2.0x P/B vs 3.6x, 17x PE vs 21x). At today's prices, EPACK offers better risk-adjusted returns.

2026-03-28 — Cash quality analysis added (EPACK vs Interarch)

• Trigger: External question — "unless they pay dividends, we're not sure they're generating cash or just manipulating profits."
• Finding: EPACK's CFO/PAT averages 1.4x over FY21-FY24 — cash generation exceeds reported profit. No red flags. FY23 dip to 0.3x was working capital build during 46% revenue growth, normalised in FY24.
• Interarch comparison added: Both companies have similar ROCE (23-25%), OPM (10%), and clean cash conversion. Key difference is capital structure (Interarch D/E 0.03 vs EPACK 0.60) and life stage — Interarch started dividends in FY25 because it's fully capitalised; EPACK retains 100% because it still has ₹300 Cr IPO capital to deploy.
• Conclusion: Zero dividend at EPACK's stage (23% ROCE, 15% PEB penetration, funded expansion) is correct capital allocation, not a governance concern.

2026-03-26 — Template v3 rewrite (classification system + expanded verdict)

• Rewritten to template v3: Added Classification (Multi-Bagger Candidate), 2-4 line Recommendation block, Strengths/Concerns (replacing kill filter language), expanded Summary Verdict with market disagreement analysis, multi-bagger math scenario table, portfolio ranking, recent developments.
• No data changes from v2 — all financials, valuations, and competitive analysis carried forward. CMP still ₹149.
• Classification rationale: Quality B (17/25) + Return Potential 2.3x/3yrs (31% CAGR) = Multi-Bagger Candidate. Base case exceeds 25% CAGR threshold.

2026-03-22 — Full framework rewrite (v2 template)

• Complete rewrite to match multi-bagger framework template — Summary Verdict, Bull/Bear cases, Compounding Engine Q&A (Q1-Q5), full financial history, DCF with shown math, P/B-ROE, Competitive Landscape with peer comparison.
• Key: Incremental ROIC at 10% diluted by undeployed IPO capital; trailing ROCE 23.7% on existing operations.
• ICRA upgraded credit rating to A+.

2026-03-19 — DCF revision (capacity-anchored)

• Revised DCF from conservative (base ₹133) to capacity-anchored (base ₹234)
• Added PEB penetration thesis: India 15% vs 70%+ global
• Quarterly volatility is order timing, not demand loss

2026-03-11 — Initial thesis created

• Built 2-model valuation: DCF (base -17%), P/B-ROE (base +158% if ROE sustains)
• Quality Score: 17/25 (Grade B). Stock at 52-week low.

Version History